Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Reducing No-Reflow Phenomenon in STEMI Patients Undergoing PCI
NCT06342141Phase 2Active, not recruiting
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of empagliflozin in ST-segment elevation myocardial infarction (STEMI) and no-reflow phenomenon (2 arms), sponsored by Instituto Nacional de Cardiología Ignacio Chávez. Primary endpoint: Incidence of Non-Reflow Phenomenon at 60 minutes. Started Aug 2024; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)no-reflow phenomenon
Beyond the preview
Go deeper on NCT06342141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342141.